Alector (ALEC) Projected to Post Quarterly Earnings on Wednesday

Alector (NASDAQ:ALEC) is expected to be issuing its Q3 2025 results before the market opens on Wednesday, November 5th. Analysts expect the company to announce earnings of ($0.40) per share and revenue of $3.4870 million for the quarter. Alector has set its FY 2025 guidance at EPS.Investors can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Wednesday, November 12, 2025 at 4:00 PM ET.

Alector (NASDAQ:ALEC) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.15. Alector had a negative net margin of 142.10% and a negative return on equity of 112.06%. The firm had revenue of $7.87 million during the quarter, compared to analysts’ expectations of $2.76 million. On average, analysts expect Alector to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Alector Stock Down 2.0%

NASDAQ:ALEC opened at $1.44 on Tuesday. The stock’s fifty day moving average price is $2.68 and its two-hundred day moving average price is $1.93. Alector has a 52-week low of $0.87 and a 52-week high of $6.14. The company has a debt-to-equity ratio of 0.13, a quick ratio of 3.78 and a current ratio of 3.78. The company has a market cap of $145.74 million, a price-to-earnings ratio of -1.24 and a beta of 0.93.

Analyst Ratings Changes

A number of equities analysts have issued reports on ALEC shares. Cowen cut shares of Alector to a “hold” rating in a research note on Wednesday, October 22nd. Wall Street Zen cut shares of Alector from a “hold” rating to a “sell” rating in a research note on Friday, September 26th. Mizuho set a $1.50 price objective on shares of Alector and gave the company a “neutral” rating in a research note on Wednesday, October 22nd. BTIG Research cut shares of Alector from a “buy” rating to a “neutral” rating in a research note on Wednesday, October 22nd. Finally, William Blair cut shares of Alector from an “outperform” rating to a “market perform” rating in a research note on Wednesday, October 22nd. One equities research analyst has rated the stock with a Buy rating, seven have issued a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat.com, Alector has an average rating of “Reduce” and a consensus target price of $3.00.

Insider Buying and Selling

In related news, Director Paula Hammond sold 14,000 shares of the business’s stock in a transaction on Tuesday, August 26th. The shares were sold at an average price of $2.36, for a total value of $33,040.00. Following the sale, the director directly owned 74,909 shares of the company’s stock, valued at approximately $176,785.24. The trade was a 15.75% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 9.70% of the company’s stock.

Institutional Trading of Alector

A number of institutional investors have recently made changes to their positions in ALEC. The Manufacturers Life Insurance Company lifted its position in shares of Alector by 153.1% in the second quarter. The Manufacturers Life Insurance Company now owns 313,578 shares of the company’s stock worth $439,000 after purchasing an additional 189,686 shares in the last quarter. Boothbay Fund Management LLC lifted its position in shares of Alector by 67.2% in the second quarter. Boothbay Fund Management LLC now owns 458,863 shares of the company’s stock worth $642,000 after purchasing an additional 184,503 shares in the last quarter. Bridgeway Capital Management LLC bought a new stake in shares of Alector in the second quarter worth $161,000. Strs Ohio bought a new stake in shares of Alector in the first quarter worth $126,000. Finally, Russell Investments Group Ltd. lifted its position in shares of Alector by 87.9% in the second quarter. Russell Investments Group Ltd. now owns 100,366 shares of the company’s stock worth $144,000 after purchasing an additional 46,945 shares in the last quarter. Institutional investors own 85.83% of the company’s stock.

About Alector

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.